Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
Kymera Therapeutics reported Q1 2026 collaboration revenue of $34.4 million, a 55% increase from the prior year, driven by a $45 million milestone payment from Gilead Sciences for the exclusive license of KT-200. The FDA granted Fast Track designation to KT-621 for moderate to severe eosinophilic asthma, adding to its prior designation for atopic dermatitis, while Phase 2b trials for both indications are ongoing with data expected in 2027.
Key figures
- Revenue
- $34.4 million
- Drug Name
- KT-621
- Guidance
- Cash runway into 2029
- Revenue Yoy
- 55%
- Deal Value Usd
- 45000000
- Phase Of Trial
- Phase 2b
- Kt 200 ind planned
- 2027
- Kt 579 data expected
- 2H26
- Kt 621 data expected ad
- mid-2027
- Kt 621 data expected asthma
- late 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.